ライフサイエンスコーパス: anticoagulate

1 grade 1 or 2 thrombosis who were or were not anticoagulated.

2 /=80 and known prior AF, only 19 (9.1%) were anticoagulated.

3 focusing on periods where patients were not anticoagulated.

4 All patients were anticoagulated.

5 he time of discharge than those who were not anticoagulated.

6 ents without specific contraindications were anticoagulated.

7 Of the 189 patients not anticoagulated, 166 (87.8%) had no major disability prio

8 propriateness of the decision to chronically anticoagulate; 2) guide clinicians in the decision of wh

9 Three of the 4 AIS patients were anticoagulated acutely, and the nontreated patient had r

10 dosing algorithm (based on data derived from anticoagulated adults) consistently overestimated warfar

11 embolic event rates differed markedly in non-anticoagulated AF patients according to the conflicting

12 In anticoagulated AF patients, a validated specific bleedin

13 ation in thromboembolic event rates in a non-anticoagulated AF population, according to different gui

14 te a clear expected net clinical benefit for anticoagulating AF patients with CHA2DS2-VASc scores of

15 who lost prior allografts to thrombosis were anticoagulated after retransplantation and 100% achieved

16 Blood was anticoagulated alone or in combination with citrate, eth

17 ts at risk for thromboembolic events are not anticoagulated, and further studies are needed to determ

18 illation at risk of stroke who are optimally anticoagulated, and reduce the burden of atrial fibrilla

19 Subject A, who was stably anticoagulated at an INR of 2.1+/-0.4 for 6 months, had

20 We investigated its role on prognosis in anticoagulated atrial fibrillation (AF) patients and det

21 r disease, 65 to 74 years of age, female) in anticoagulated atrial fibrillation (AF) patients.

22 are not related to stroke in a contemporary anticoagulated atrial fibrillation population.

23 yl-L-arginine chloromethylketone and citrate-anticoagulated blood early (15 and 30 minutes) and late

24 Meningococci were added to anticoagulated blood from 12 healthy adults vaccinated w

25 elae or Bartonella elizabethae DNA from EDTA-anticoagulated blood samples obtained from four dogs was

26 xperimental study in which heparin- and EDTA-anticoagulated blood samples were collected from 101 HIV

27 induced platelet aggregation was measured in anticoagulated blood under static and arterial flow cond

28 Decay in EDTA-anticoagulated blood was not significant after 6 h (bDNA

29 ivation and phagocytosis of microbes in full anticoagulated blood.

30 In a cross-sectional study of anticoagulated children from 5 tertiary care centers, 12

31 d before the event), of whom only 14.5% were anticoagulated despite 82.3% having a CHA2DS2VASC score

32 history of stroke were more likely to remain anticoagulated despite a successful outcome from LARFA.

33 population has steadily risen where 5.9% of anticoagulated dialysis patients are started on dabigatr

34 ely((R)) recommendations include: (1) do not anticoagulate for more than 3 months in patients experie

35 All were systemically anticoagulated for a period of 6-8 weeks after diagnosis

36 We included 40 404 patients anticoagulated for atrial fibrillation, aged 65+, within

37 Also, rates of major bleeding episodes in anticoagulated hemodialysis patients with AF are high.

38 Fresh, anticoagulated human blood was recirculated for 2 hours

39 on microcarrier beads and incubated with non-anticoagulated human blood were used to study binding of

40 hibited thrombosis in PPACK- but not heparin-anticoagulated human blood.

41 Leukocytes were isolated from anticoagulated human or mouse (C57BL/10J) blood using co

42 nders spent greater proportions of time over-anticoagulated in the first 90 days of treatment (median

43 kine profile was distinct from that of fully anticoagulated, LPS-stimulated blood, which showed level

44 ls in the lung was markedly inhibited in the anticoagulated mice.

45 g antiplatelet therapy among therapeutically anticoagulated non-ST-segment-elevation myocardial infar

46 Patients were anticoagulated orally with either adjusted-dose warfarin

47 We recruited 965 consecutive anticoagulated outpatients with permanent or paroxysmal

48 arin compared with 21% in those who were not anticoagulated (P =.2).

49 he European tPA license precludes its use in anticoagulated patients altogether.

50 ding complications occurred in alternatively anticoagulated patients and in fondaparinux-treated pati

51 tigate predictors of bleeding in a cohort of anticoagulated patients and to evaluate the predictive v

52 fibrillation was significantly higher in non-anticoagulated patients as compared with patients receiv

53 Five non-anticoagulated patients experienced nonfatal thromboembo

54 ivo studies demonstrated that platelets from anticoagulated patients had decreased VEGF release and a

55 e for cardiovascular events and mortality in anticoagulated patients with AF, consistent with the rel

56 In this cohort of anticoagulated patients with AF, the sole presence of di

57 ing and cardiovascular events in a cohort of anticoagulated patients with AF.

58 Bleeding risk represents a major concern in anticoagulated patients with atrial fibrillation (AF).

59 dicated stroke or systemic embolic events in anticoagulated patients with atrial fibrillation in the

60 ence of allograft thrombosis was observed in anticoagulated patients with hypercoagulable states.

61 /=80 years, of which 124 (33.6%) were in non-anticoagulated patients with known prior AF.

62 of all disabling/fatal strokes occur in non-anticoagulated patients with known prior AF.

63 ommend a heparin-bridging strategy (HBS) for anticoagulated patients with moderate/high risk for thro

64 TUR syndrome, but requires further study in anticoagulated patients.

65 Anticoagulated peripheral venous blood from 19 patients

66 bility of APC to inactivate factor Va and to anticoagulate plasma.

67 These data indicate that EDTA-anticoagulated plasma is the most suitable and stable ma

68 -, heparin-, and acid citrate dextrose (ACD)-anticoagulated plasma samples were comparable.

69 nd vWF multimeric patterns in patients' EDTA-anticoagulated plasma samples.

70 ADAMTS13 activity in citrate-anticoagulated plasma was enhanced approximately 2-fold

71 yrene surface and exposed to human lepirudin-anticoagulated plasma, the bound peptide captured factor

72 The EDTA-anticoagulated plasmas showed the smallest decrease in H

73 serum as well as in EDTA-, ACD-, and heparin-anticoagulated plasmas stored at -70 degrees C.

74 IV-1 RNA detected in EDTA-, heparin-, or ACD-anticoagulated plasmas.

75 of 53 nM in citrate buffer, 110 nM in PPACK anticoagulated PRP, and 4 nM in solid-phase GPIIb-IIIa c

76 mean decrease = 0.317 log units) and heparin-anticoagulated samples (mean decrease = 0.384 log units)

77 antagonists in vitro may be overestimated in anticoagulated samples of blood and best achieved in viv

78 Symptomatic patients who were anticoagulated showed a trend toward greater neurologic

79 90% of study patients when prophylactically anticoagulating study patients with hypercoagulable stat

80 hPF4(+) animals, although these animals were anticoagulated systemically.

81 epatic, and bone marrow function; adequately anticoagulated thromboembolism; a urine protein to creat

82 02 log units) as cell-free plasma or as EDTA-anticoagulated whole blood (mean SD = +/- 0.109 log unit

83 Platelet-bound vWF in patients' EDTA-anticoagulated whole blood samples; vWF proteinase activ

84 hemoglobin (HbA1c) levels were measured from anticoagulated whole blood using an automated affinity c

85 Anticoagulated whole blood was added to the cartridge, a

86 article, we demonstrate that in serum and in anticoagulated whole blood, moderate concentrations of h

87 on was 50 organisms/ml of mock-infected EDTA anticoagulated whole blood.

88 ads, coated with CHC, and incubated with non-anticoagulated whole human blood.

89 We attempted but failed to anticoagulate with warfarin.

90 assist device-supported patients are usually anticoagulated with a combination of aspirin and vitamin

91 Groups 2-4 were anticoagulated with aspirin and Plavix, Lovenox, or Coum

92 nd to inhibit platelet aggregation in plasma anticoagulated with citrate (for ADP, mean+/-SD IC(50)=1

93 er the reduced Ca2+ concentrations in plasma anticoagulated with citrate affect Integrilin binding to

94 tin in response to ADP was greatest in blood anticoagulated with citrate compared with CTI and all ot

95 let aggregation was greater in blood samples anticoagulated with citrate versus D-phenylalanyl-L-prol

96 at platelet concentrates prepared from blood anticoagulated with citrate were unsuitable for transfus

97 re resuscitated by reinfusion of shed blood (anticoagulated with citrate-phosphate-dextrose) and crys

98 Fibrinogen was added to blood anticoagulated with corn trypsin inhibitor (a specific i

99 ess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.

100 thrombolysis, it is unclear whether patients anticoagulated with DE can be thrombolysed.

101 ced platelet activation was greater in blood anticoagulated with heparin compared with an equipotent

102 clotting, patients with malignancy are often anticoagulated with heparin products, which paradoxicall

103 so significantly prolonged the ACTs of blood anticoagulated with the direct thrombin inhibitors hirud

104 All patients were anticoagulated with warfarin for > or = 3 months after L

105 clinical outcomes among patients chronically anticoagulated with warfarin or apixaban.

106 hiari syndrome (BCS) traditionally have been anticoagulated with warfarin postoperatively.

107 was also inhibited by tPA-S(481)A in WT mice anticoagulated with warfarin.